Ousted ARPA-H Chief Renee Wegrzyn Bets Startup on Science's 'Magic Hands'

By Nathan Brooks

Renee Wegrzyn, the inaugural director of the White House's Advanced Research Projects Agency for Health, lost her job to a change of administration — and her response was to cofound a startup aimed at one of science's least glamorous bottlenecks.

The company is Transfyr. The problem it targets is what Wegrzyn calls the "magic hands" issue: the tacit, often indescribable laboratory skill that lets a few scientists deliver great results over and over while others can't reproduce them.

Wegrzyn laid out the thesis in an interview on the Rapid Response podcast, hosted by former Fast Company editor-in-chief Robert Safian. Her argument is blunt: until you can capture and transfer technique itself, AI's promises in medicine stay stuck at the starting line.

What are 'magic hands' in a lab?

Wegrzyn's framing is domestic. "You probably have your favorite dish, or your parents' or grandparents' favorite dish. Sometimes they just have the magic hands. Nobody can cook it like they do," she said. "And that happens in science as well. There are some scientists who just have the knack and can deliver really great science over and over."

The catch: those experts often can't articulate what they're doing. "It's an art in some ways," she said.

Transfyr's pipeline attacks this with computer vision and perception tools that record the work of science as it happens. Wegrzyn's example: if a protocol says "mix the cells," one researcher inverts the tube gently while another rigorously shakes or vortexes it — which can destroy the sample. Those small decisions, compounded across hours of experimentation, are the difference between a replicable result and a dead end.

Why this matters for anyone commercializing research

What does this change for practitioners trying to move a paper into a product? Wegrzyn saw the failure mode firsthand at DARPA and ARPA-H.

"Usually, the way a breakthrough is first communicated to the world is through a research publication, a Science or Nature paper. That paper is not a product. It's not commercializable. It's not ready for a patient that day," she said. "That's the starting gun for what is going to happen."

In her telling, the ARPAs excel at reaching the initial demonstration but "following through and delivering is not a 100% guaranteed activity." At ARPA-H she pushed a fix: bring in the final users of a technology during development, so that by the last day of a program they were already demanding the product — rather than a first customer contact arriving after the grant money ran out, which she called common at traditional funding bodies.

Transfyr treats knowledge transfer as a series of handoffs. The company deploys its technology both in the originating lab, to understand what mattered about a discovery, and in receiving labs, to watch how others reproduce it. Instead of scientists "looking over each other's shoulders and saying, 'Oh, you're doing it a little wrong,'" Wegrzyn said the video-connectedness accelerates iteration between labs.

The firing she didn't take personally

Wegrzyn's exit was unusual. She was a presidential appointee but term-limited, so she served through the transition and a few weeks into the new administration — and had previously served in what she calls "Trump one." She used the window to make the case for the agency she built.

"I was able to show them what we were building and convince them that it was worth keeping around. I couldn't be more proud of the agency and its perseverance," she said.

DARPA, her reference point, has run for almost 80 years. She hopes ARPA-H, created to accelerate health breakthroughs, matches that longevity.

The competitiveness warning

Wegrzyn also flagged a bigger risk. For the 80 years since World War II, the U.S. has led the world in science and engineering — meaning no working American scientist has practiced in an era when the country wasn't winning. "I genuinely believe we may lose that competitiveness, that edge, that incumbency, and I'm not sure I see us fighting for it in the way that we should be," she said.

She frames the moment through Sputnik. "What is the Sputnik moment now?" she asked — noting that every individual has a personal Sputnik moment, usually health-related; hers was her mother's cancer diagnosis.

The so-what for operators: if Transfyr can standardize the tacit craft inside elite labs, it shortens the distance between a Nature paper and a product a patient can actually use — the exact gap where most federally funded breakthroughs stall today.